EGFR基因多态性与宫颈癌放化疗近期疗效的关系  

The Association between Single Nucleotide Polymorphisms of Epidermal Growth Factor Re- ceptor and Short-Term Response to Radiochemotherpy in Cervical Cancer

作　　者：樊晓妹[1] 李魁秀[1] 李琰[2] 房朝辉[1] 牛书怀[1] 金鸽[1] 

机构地区：[1]河北医科大学第四医院,河北石家庄050000 [2]河北省肿瘤研究所,河北石家庄050000

出　　处：《实用妇产科杂志》2014年第1期33-36,共4页Journal of Practical Obstetrics and Gynecology

摘　　要：目的：探讨表皮生长因子受体（EGFR）基因R497K及．216G／T单核苷酸多态性（SNP）与宫颈癌患者放化疗近期疗效的关系。方法：应用聚合酶链反应一连接酶检测反应方法，检测了196例接受单纯放疗或放疗合并化疗的宫颈癌的EGFR基因R497K、-216G／T两个SNP。结果：与携带R497KG／G基因型组相比，携带A／A基因型组放疗敏感性差异有统计学意义（P〈0．05），校正OR值为0．244（95％C10．087～0．680）；与携带-216G／G基因型组相比，携带G／T＋T／T基因型组放疗敏感性差异无统计学意义，校正OR值为2．412（95％C10．856—6．797）。与携带R497KG／G基因型相比，携带A／A基因型组复发转移风险差异有统计学意义（P〈0．05），校正OR值为0．248（95％C10．078～0．786）；与携带-216G／G基因型的患者相比，携带G／T4-T／T基因型组复发转移风险差异无统计学意义（P〉0．05），校正OR值为1．027（95％C10．324～3．253）。结论：EGFR基因R497K多态性位点与宫颈癌患者放化疗近期疗效及复发或转移风险相关，可能是预测宫颈癌放疗近期疗效及复发或转移的预测指标。Objective：This study was designed to investigate the association of EGFR R497K and -216G/ T single nucleotide polymorphisms with radiochemotherapy response in cervical cancer. Methods ：The geno- type of EGFR R497K and -216G/T were analyzed by polymerase chain reaction-ligation detection reaction （PCR-LDR） in 196 cervical cancer patients whounderwent radiotherapy alone or radiotherapy combined with chemotherapy. Results：Compared with patients with R497K G/G genotype,the patients with A/A genotype had a significantly higher sensitivity to radiochemotherapy treatment （adjusted OR = 0. 244,95% CI 0. 087 ~ 0. 680）. Compared with the patients with -216G/G genotype,the patients with G/T ＋ T/T genotypes had no significant difference in sensitivity to radiochemotherapy（ adjusted OR =2.412,95% CI 0. 856 -6. 979 ）. Com- pared with the patients with R497K G/G genotype,the patients with A/A genotype had a decreased risk of recurrencemetastasis （ adjusted OR = 0. 248,95% CI 0. 078 ~ 0. 786, P 〈 0. 05）. Compared with the paitents with -216G/G genotype, the patients with G/T ＋ T/T genotypes had no significant difference in the risk of re- currence/metastasis（adjusted OR = 1. 027,95% CI 0. 324 -3. 253）. Conclusions： In our study, the R497K polymorphisms have a relationship with treatment response and the risk of recurrencemetastasis for cervical cancer. R497K SNP might be a genetic marker for prediction radiochemotherapy response and the risk of re- currence/metastasis of patients with cervical cancer.

关 键 词：宫颈癌 表皮生长因子受体 单核苷酸多态性 放疗 化疗 

分 类 号：R737.33[医药卫生—肿瘤]